Skip to main content

Multi-Market Submission Strategy Including KSA

Leveraging EU MDR documentation​

Manufacturers with existing CE marking under EU MDR are best positioned to enter the Saudi market because:

  • SFDA classification rules are identical to EU MDR Annex VIII
  • The technical file structure (Annex 3 of MDS-REQ 1) mirrors EU MDR technical documentation
  • Essential Principles align with EU MDR GSPR (Annex I)
  • Risk management, clinical evaluation, and labelling requirements follow the same international standards

While CE marking does not replace MDMA, manufacturers can reuse most EU technical documentation with adaptations for SFDA-specific requirements (DoC template, AR details, Arabic labelling where needed).

Recommended sequencing for multi-market entry​

  1. EU MDR / FDA — establish core technical file and clinical evidence
  2. Saudi Arabia (SFDA) — adapt technical file to MDS-REQ 1, appoint AR, apply via GHAD
  3. UAE, Kuwait, Bahrain — leverage SFDA registration as regional base; submit to each authority
  4. Other GCC markets — coordinate with local distributors/ARs in each country

Key adaptations required for SFDA vs EU MDR​

ElementEU MDRSFDA adaptation needed
DoC templateOwn formatMust use SFDA Annex 14 template
AR on labelsEU AR name/addressSaudi AR name/address
LanguageLocal EU language + EnglishEnglish + Arabic for home-use
Submission portalEUDAMEDGHAD
Certificate holderManufacturerAR

Further reading​

Post-SFDA Approval: Timing for GCC Expansion

After SFDA MDMA is granted, manufacturers typically apply to other GCC markets within 3–6 months to leverage momentum and market positioning. However, some manufacturers defer UAE registration (the second-largest GCC market) if it requires separate clinical evidence or local manufacturing partnerships. A typical GCC entry sequence is: Saudi Arabia (SFDA) → UAE (MOHAP/DHA) → Kuwait and Bahrain (parallel) → Qatar and Oman (as market opportunity permits). Coordinate with your regional distributor or AR network to align timelines.